Dr. Elias Michael Abboud, M.D. Allergy & Immunology Medicare: May Accept Medicare Assignments Practice Location: 261 Old York Rd, Ste 325, Jenkintown, PA 19046 Phone: 215-572-7900 Fax: 215-884-3901 |
News Archive
In a study that included elderly men and women without preexisting cardiovascular disease, major and minor electrocardiographic abnormalities were associated with an increased risk of coronary heart disease (CHD) events and improved the prediction of CHD events such as heart attack, beyond traditional cardiovascular risk factors, according to a study in the April 11 issue of JAMA.
A new report has concluded that the racial disparities between cancer deaths among white and black Americans is on the decline.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of a new Cooperative Research and Development Agreement with Los Alamos National Security, LLC for the development of a waveguide-based integrated optical biosensor platform for the detection of disease causing pathogens.
› Verified 6 days ago